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ABSTRACT
Background: In sarcoidosis, blood monocytes, circulating precursors of granuloma macrophages, display
enhanced inflammatory cytokine production, reduced expression of the regulatory (inhibitory) receptor
CD200R, and altered subsets defined by CD14 and CD16. Regulatory receptors serve to dampen monocyte
and macrophage inflammatory responses. We investigated the relationship between monocyte subsets and
regulatory receptor expression in sarcoidosis.
Methods: Multiparameter flow cytometry was used to perform detailed analyses of cell surface regulatory
molecules on freshly isolated blood immune cells from patients with chronic pulmonary sarcoidosis and
age-matched healthy controls.
Results: 25 patients with chronic pulmonary sarcoidosis (median duration of disease 22 months) who were
not taking oral corticosteroids or other immunomodulators were recruited. Nonclassical monocytes were
expanded in sarcoidosis and exhibited significantly lower expression of regulatory receptors CD200R,
signal regulatory protein-α and CD47 than classical or intermediate monocytes. In sarcoidosis, all three
monocyte subsets had significantly reduced CD200R and CD47 expression compared with healthy
controls. A dichotomous distribution of CD200R was seen on classical and intermediate monocytes in the
sarcoidosis population, with 14 out of 25 (56%) sarcoidosis patients having a CD200Rlow phenotype and
11 out of 25 (44%) having a CD200Rhigh phenotype. These distinct sarcoidosis monocyte phenotypes
remained consistent over time.
Conclusions: Nonclassical monocytes, which are expanded in sarcoidosis, express very low levels of
regulatory receptors. Two distinct and persistent phenotypes of CD200R expression in classical and
intermediate monocytes could be evaluated as sarcoidosis biomarkers.
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Sarcoidosis is characterised by granulomas composed of activated monocyte-derived macrophages [1].
Studying circulating blood monocytes offers a window to granuloma macrophage biology and, unlike
sarcoid tissue biopsies, allows repeated sampling. Research in sarcoidosis has identified alterations in
circulating monocyte populations defined by expression of surface receptors CD14 (lipopolysaccharide
co-receptor) and CD16 (low-affinity receptor for IgG). Reduced classical (CD14++/CD16−) monocytes and
increased CD16-expressing nonclassical (CD14+/CD16++) or intermediate (CD14++/CD16+) monocytes
have been reported [2–5]. Enhanced production of inflammatory cytokines by sarcoidosis monocytes was
associated with reduced expression of the regulatory receptor CD200R [2], which serves to dampen
immune responses. CD200R deficiency in animals leads to enhanced production of tumour necrosis factor
(TNF) [6, 7], a critical driver of granulomatous inflammation. Therefore, relative lack of CD200R could
contribute to the exaggerated inflammation seen in chronic sarcoidosis. The relationship between
sarcoidosis monocyte subsets and expression of CD200R and other regulatory receptors is unknown.
Methods
Subjects
Patients with chronic pulmonary sarcoidosis were recruited from the sarcoidosis clinic at Hull University
Teaching Hospitals NHS Trust (Hull, UK). Patients were diagnosed by a specialist interstitial lung disease
physician according to international guidance [8]. Exclusion criteria included current tobacco smoking or
therapy with oral corticosteroids or other immunomodulatory drugs, which could independently affect
monocyte phenotype. Healthy controls were age- and sex-matched with the patient cohort. Controls were
volunteers without sarcoidosis or significant lung disease who were nonsmokers and were not taking oral
corticosteroids or immunosuppressant medication. Detailed medical histories were not obtained from
healthy controls nor were pulmonary function tests or blood investigations performed. A statistical power
calculation was not performed for this exploratory study. Ethical approval was obtained from the
Yorkshire and Humber Research Ethics Committee (REC 16/YH/0118) and participants gave written
informed consent.
Immune cell phenotyping
Blood was collected in sodium heparin tubes (BD, Oxford, UK) and processing was started within 1 h.
Peripheral blood mononuclear cells (PBMCs) were isolated using density gradient centrifugation [2]. For
immunophenotyping, live unfixed PBMCs were stained with saturating combinations of fluorescent
antibodies (supplementary tables S1 and S2) and multiparameter flow cytometry was used to analyse
antibody binding, allowing discrimination of surface receptor expression on cellular subsets. Details of the
immunophenotyping procedures can be found in the supplementary material.
TABLE 1 Demographic and clinical profiles of patients with sarcoidosis and healthy controls
Sarcoidosis Controls
Patients 25 12




Time since diagnosis months 22 (0–193)





Angiotensin converting enzyme U·L−1# 94 (9–440)
Blood lymphocyte count ×109 L−1¶ 0.86 (0.29–2.03)
FEV1 % pred 93 (54–126)
FVC % pred 95 (64–129)
FEV1/FVC 0.81 (0.49–0.91)
Data are presented as n or median (range). FEV1: forced expiratory volume in 1 s; FVC: forced vital
capacity. #: reference range 8–65 U·L−1; ¶: reference range 0.8–3.4×109 L−1.
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Immunohistochemistry
The procedure for staining tissue sections for CD200L and CD200R was adapted from CAWKWELL et al. [9].
Antibodies were a polyclonal goat CD200L antibody (AF2724; R&D Systems, Abingdon, UK), normal goat
IgG control (AB-108-C; R&D Systems), mouse monoclonal IgG1 anti-human CD200R (OX108, MCA
2282T; AbD Serotec/Bio-Rad, Kidlington, UK) and mouse monoclonal control IgG1 antibody (MOPC-21,
400101; Biolegend, London, UK).
Statistical analyses
Statistical significance was determined using the Mann–Whitney U-test or Kruskal–Wallis test for
nonparametric distributions and the t-test, one-way ANOVA or two-way ANOVA for parametric
distributions. Multiple comparisons underwent Šídák or Tukey’s or post hoc analyses as appropriate.
Pearson’s Chi-squared or Fisher’s exact tests were used to examine associations between categorical
variables. Analyses were performed using Prism (GraphPad, La Jolla, CA, USA).
Results
Patient demographics
25 treatment-naive patients with chronic pulmonary sarcoidosis were recruited. Baseline characteristics of
the patients are presented in table 1. All participants were of White ethnicity, reflecting the local
population.
Nonclassical monocytes are increased in sarcoidosis and express low levels of CD200R
Sarcoidosis patients had significantly increased proportions of nonclassical monocytes and significantly
lower proportions of classical monocytes compared with controls (figure 1). Nonclassical monocytes
expressed significantly lower levels (10–15%) of CD200R than intermediate or classical monocytes in both
























































FIGURE 1 Patients with sarcoidosis have increased nonclassical monocytes and reduced classical monocytes
compared with controls. Flow cytometric analysis of peripheral blood mononuclear cells (PBMCs) was used
to define monocyte subsets based on expression of CD14 and CD16. Ungated PBMCs are shown here for
illustrative purposes. a) Monocytes were defined as classical (CD14++/CD16–/low: “C”), intermediate (CD14++/
CD16+: “I”) or nonclassical (CD14+/CD16++: “NC”). b–d) Proportions of b) classical, c) intermediate and
d) nonclassical monocyte subsets within total blood monocytes for patients with sarcoidosis (n=25)
and healthy controls (n=12). Individual data points are presented along with median and interquartile range.
**: p<0.01 (Mann–Whitney U-test).
https://doi.org/10.1183/23120541.00804-2020 3
INTERSTITIAL LUNG DISEASE | S.D. FRASER ET AL.
Dichotomous populations of monocyte CD200R expression in sarcoidosis
Patients with sarcoidosis had significantly lower expression of CD200R on all monocyte subsets compared
with controls (figure 2). In the sarcoidosis cohort, CD200R expression on classical and intermediate
monocytes was not normally distributed. Normal quantile–quantile plots (supplementary figure S2)
confirmed bimodal populations with inflection points delineating CD200Rhigh from CD200Rlow at a
geometric mean fluorescence intensity (GMFI) of ∼300.
To establish whether CD200R expression on monocytes was stable or varied over time, patients were
tracked every 2 months for up to 1 year in a longitudinal study. The two distinct sarcoidosis patient
populations with CD200Rhigh and CD200Rlow classical and intermediate monocyte subsets maintained
their phenotypes throughout follow-up (figure 3). No individual switched between populations over time.
11 patients (44%) exhibited high CD200R expression on classical and intermediate monocytes (median
(range) GMFI 505 (359–664)) and 14 (56%) had low CD200R expression (median (range) GMFI 157
(70–276)). Most control subjects had high CD200R expression on classical and intermediate monocytes,
but we also observed a low classical monocyte CD200R phenotype in three of the 12 healthy controls.
CD200Rhigh or CD200Rlow monocyte phenotypes in sarcoidosis patients were not associated with age, sex,
extent of chest radiograph changes, lung function, serum angiotensin converting enzyme activity,
C-reactive protein or blood cell counts (table 2). Comorbidities and medication use were evenly distributed
across the two monocyte phenotypes (data not shown).
The effect of systemic corticosteroid therapy on monocyte subsets and CD200R expression was examined
in three patients who progressed to need treatment with oral prednisolone during follow-up. Oral
prednisolone therapy for 2 months (20 mg·day−1) tended to normalise monocyte subsets (figure 4), with
post-treatment increases in classical monocytes and decreases in nonclassical monocytes. Statistical
significance could not be demonstrated with only three pairs of data. In contrast, prednisolone therapy










































































































FIGURE 2 Nonclassical monocytes express low levels of CD200R and expression of CD200R is lower on all monocyte subsets in patients with
sarcoidosis compared with healthy controls. GMFI: geometric mean fluorescence intensity. a) Representative flow cytometry histograms from a
healthy control subject comparing CD200R expression on classical, intermediate and nonclassical monocytes compared with isotype control
antibody. b, c) Representative heat-map dot plots from b) a healthy control subject demonstrating low CD200R on nonclassical monocytes and c) a
patient with sarcoidosis showing reduced CD200R expression on sarcoidosis monocyte subsets compared with the healthy control. On these
pseudo-colour plots, orange indicates higher CD200R expression and green indicates lower CD200R expression. d–f ) Expression of CD200R on
d) classical, e) intermediate and f) nonclassical monocyte subsets in sarcoidosis patients and controls. Note the small y-axis scale for
nonclassical monocytes. Individual data points are presented along with median and interquartile range. *: p<0.05; **: p<0.01 (Mann–Whitney
U-test).
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Expression of regulatory receptors signal regulatory protein-α, CD47 and interleukin-10R on
sarcoidosis monocytes
CD200R is one of several inhibitory receptors that dampen inflammatory responses in monocytes, so we
studied whether other regulatory molecules were differentially expressed by monocyte subsets. We focused
on molecules that, like CD200R, are known to regulate monocyte inflammatory responses, namely signal
regulatory protein-α (SIRP-α, which binds CD47 and surfactant proteins), CD47 (the ligand for SIRP-α and
receptor for thrombospondin-1 that delivers an anti-phagocytic signal) and interleukin (IL)-10R (the
receptor for IL-10, an anti-inflammatory cytokine). Expression of CD47 and SIRP-α was significantly lower
on nonclassical monocytes compared with classical or intermediate monocytes, whereas expression of IL-10R
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FIGURE 3 CD200R expression on sarcoidosis classical and intermediate monocytes is dichotomous and consistent over time. GMFI: geometric
mean fluorescence intensity. Patients with sarcoidosis in a longitudinal cohort (n=19) underwent serial measurements of CD200R expression on
a) classical, b) intermediate and c) nonclassical monocyte subsets. Each patient is presented by a different coloured line.
TABLE 2 Characteristics of sarcoidosis patients stratified by monocyte CD200R phenotype
CD200Rlow CD200Rhigh p-value
Patients 14 11





Angiotensin converting enzyme U·L−1 92 (52–136) 104 (74–155) 0.695
C-reactive protein mg·L−1 2.0 (1.4–5.5) 2.8 (0.6–9.6) 0.217
Age years# 53.5 (40–73) 50.0 (38–67) 1.00
FEV1 % pred 99 (69–110) 92 (82–113) 0.428
FVC % pred 103 (76–115) 90 (82–114) 0.428
FEV1/FVC 0.79 (0.75–0.84) 0.83 (0.76–0.86) 0.238




White blood cell count ×109 L−1 5.4 (4.15–6.20) 4.3 (3.50–5.60) 0.196
Lymphocyte count ×109 L−1 0.93 (0.74–1.41) 0.74 (0.62–1.02) 0.279
Monocyte count ×109 L−1 0.55 (0.44–0.72) 0.42 (0.24–0.70) 0.252
Neutrophil count ×109 L−1 3.42 (2.70–3.98) 2.70 (2.33–3.97) 0.336
Eosinophil count ×109 L−1 0.15 (0.13–0.23) 0.20 (0.08–0.21) 0.797
T-lymphocyte count ×109 L−1 0.61 (0.36–0.91) 0.48 (0.33–0.63) 0.403
CD4+ T-lymphocyte count ×109 L−1 0.36 (0.22–0.70) 0.30 (0.16–0.45) 0.596
CD8+ T-lymphocyte count ×109 L−1 0.20 (0.11–0.40) 0.17 (0.09–0.21) 0.290
B-lymphocyte count ×109 L−1 0.16 (0.07–0.21) 0.14 (0.08–0.23) 0.499
Natural killer cell count ×109 L−1 0.17 (0.12–0.22) 0.15 (0.09–0.26) 0.450
Data are presented as n or median (interquartile range), unless otherwise stated. FEV1: forced expiratory
volume in 1 s; FVC: forced vital capacity. #: median (range). Statistical comparisons by nonparametric
independent samples median test or Pearson’s Chi-squared test.
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Comparing patients with sarcoidosis and healthy controls demonstrated significantly reduced expression of
CD47 on all monocyte subsets in sarcoidosis (figure 5). IL-10R expression was reduced only on
intermediate monocytes in patients with sarcoidosis compared with controls, but not on other subsets.
SIRP-α expression was similar in controls and sarcoidosis patients.
Distribution of CD200R and CD200L in sarcoidosis granulomas
To gain a preliminary view of how macrophage regulatory receptors may interact with ligands within a
sarcoidosis granuloma, we stained sarcoidosis biopsies for the receptor–ligand pairing of CD200R and
CD200L. Figure 6 shows the spatial relationship between CD200R-expressing granuloma macrophages and
neighbouring CD200L-positive lymphocytes and fibroblasts.
Discussion
Understanding the cellular and molecular drivers of persistent and progressive sarcoidosis will be an
important step towards identifying new targets for treatment. Chronic, nonresolving sarcoidosis is
characterised immunologically by heightened inflammatory responses of tissue granuloma macrophages
and their precursors, circulating blood monocytes [2, 5, 10–14]. Cell surface regulatory receptors such as



















































































































FIGURE 4 Oral corticosteroid therapy for sarcoidosis normalises monocyte subsets but has no effect on
monocyte CD200R expression. GMFI: geometric mean fluorescence intensity. Pre- and 2-month
post-steroid treatment data for three sarcoidosis patients who were treated with oral prednisolone 20 mg·day−1.
a, c, e) Percentages of classical, intermediate and nonclassical monocytes, respectively. b, d, f ) CD200R
expression on the respective monocyte subsets.
https://doi.org/10.1183/23120541.00804-2020 6
INTERSTITIAL LUNG DISEASE | S.D. FRASER ET AL.
production of TNF, which is a key cytokine driving granuloma formation and persistence [15, 16]. Altered
regulatory receptor expression is a potential mechanism contributing to persistent and progressive
granulomatous inflammation in sarcoidosis.
We provide the first description that monocyte subsets have distinct expression profiles of regulatory
receptors. Nonclassical monocytes exhibited much lower expression of CD200R, SIRP-α and CD47 than
classical or intermediate monocytes. Moreover, in sarcoidosis all monocyte subsets had reduced CD200R
and CD47 expression compared with healthy controls, providing an additional explanation for the overall
reduced regulatory receptor profile. However, there is not a global reduction of all regulatory molecules in
sarcoidosis, since expression levels of SIRP-α or IL-10R were similar to controls.
In health, most (∼90%) monocytes are classical CD14++/CD16− cells [17]. The remainder comprise
CD16-positive nonclassical monocytes which exhibit higher stimulated TNF production [18] and a low
frequency intermediate (CD14++/CD16+) monocyte population. A developmental relationship between
monocyte subsets has been described, with sequential increase in first intermediate then nonclassical
monocytes [19]. Distinguishing nonclassical from intermediate monocytes within the CD16-positive
population can be challenging [4, 17, 20], so it is difficult to compare studies directly. In the present study,
we identified a clear increase in nonclassical monocytes in sarcoidosis, whereas previous studies reported



























































































































































































FIGURE 5 Monocyte subsets have distinct expression profiles of signal regulatory protein-α (SIRP-α), CD47 and interleukin (IL)-10R in sarcoidosis
and healthy controls. Expression of a–c) SIRP-α, d–f ) CD47 and g–i) IL-10R on a, d, g) classical, b, e, h) intermediate and c, f, i) nonclassical
monocyte subsets in patients with sarcoidosis (n=25) and healthy controls (n=7). Individual data points are presented along with median and
interquartile range. **: p<0.01; ***: p<0.001; ****: p<0.0001 (Mann–Whitney U-test).
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findings can be explained by increased refinement of monocyte gating. By utilising a fluorophore with a
high stain index for CD16, adopting an angled gate between intermediate and nonclassical monocyte
populations, and employing a robust gating protocol across all populations, the present study presents a
more precise separation of monocyte subsets than we previously used. Although we did not refine
discrimination of intermediate and nonclassical monocytes with additional markers such as 6-sulfo
LacNAc (slan) [4], we have shown that CD200R expression clearly distinguishes nonclassical and
intermediate monocytes, supporting the validity of our gating strategy and suggesting that CD200R has
both functional and phenotypic importance and could be incorporated in future studies. Moreover,
CD200R could be used in future studies as a marker of nonclassical monocytes.
Distribution of CD200R expression on classical and intermediate monocytes was dichotomous, such that
patients with sarcoidosis could be divided into CD200Rhigh and CD200Rlow groups. The stability of this
monocyte CD200R phenotype over time suggests two distinct and consistent phenotypes of sarcoidosis. In
our previous study, there was a dichotomous distribution of CD200R on total monocytes in sarcoidosis,
whereas all of the 17 healthy controls had a CD200Rhigh phenotype. In the present study, three of the 12
controls exhibited a CD200Rlow phenotype on classical and intermediate monocytes. This difference
between the studies may be explained by careful age matching of the control with patient groups in the
present study. We cannot rule out the possibility that the ethnically White population studied comprises
two subpopulations, one with high and one with low CD200R expression, and that individuals with low
expression are over-represented within a sarcoid patient group.
Immunohistochemistry showed CD200R-expressing macrophages concentrated in the central core of the
sarcoidosis granuloma, surrounded by CD200L-expressing lymphocytes and fibroblasts. We anticipate that
within the dynamic milieu of a sarcoidosis granuloma, CD200R on macrophages will be ligated by
CD200L on neighbouring cells as they migrate and interact with each other.
We provide the first description of significantly reduced regulatory receptor expression on nonclassical
monocytes. Expansion of these nonclassical monocytes in sarcoidosis, together with reduced levels of
specific regulatory molecules (CD200R and CD47) on all sarcoidosis monocyte subsets compared with
controls, will favour heightened inflammatory responses. This sarcoidosis monocyte phenotype could be






FIGURE 6 Distribution of the regulatory receptor CD200R and its ligand CD200L in sarcoidosis granulomas:
transbronchial lung biopsy samples from two patients with sarcoidosis stained for a) CD200L and b) CD200R,
with respective isotype control antibody staining in c) and d). f: fibroblasts; h: histiocytes (macrophages).
Original magnification ×100.
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